[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
June 3, 1974

Aspirin and Diabetic Retinopathy

JAMA. 1974;228(10):1274. doi:10.1001/jama.1974.03230350046032

Kwaan and his co-workers,1 having previously observed a diabetic patient with disseminated intravascular coagulation consequent to increased platelet aggregation, had studied 87 other mature-onset diabetic subjects of whom 77 exhibited platelet aggregation-enhancing activity. The degree of such activity did not correlate with plasma levels of lipoproteins, triglycerides, free fatty acids, the free fatty acids to albumin molar ratio, or such complications as occlusive diseases of large arteries and neuropathy. However, there was distinct correlation with the occurrence of diabetic nephropathy, retinopathy, and the duration of the disease.

More recently, as a follow-up to their earlier observations, the same group of authors2 conducted further studies of the correlation of platelet aggregation-enhancing activity with diabetic retinopathy. The method for measuring the degree of activity permitted expression of an aggregation index (AI).

In diabetic patients without retinopathy or with early retinopathy, a percentage increase of AI was lacking or slight, and